Milk product compositions

A cell construct, comprising:

• a. a three dimensional scaffold having an exterior surface, an interior surface defining an interior cavity/basal chamber, and a plurality of pores extending from the interior surface to the exterior surface;
• b. a matrix material disposed on the exterior surface of the three-dimensional scaffold;
• c. a culture media disposed within the interior cavity/basal chamber and in fluidic contact with the internal surface;
• d. a plurality of plasma cells disposed on the matrix material;
• and
• e. an at least 70% confluent monolayer of polarized mammary cells disposed on the plurality of plasma cells, wherein the mammary cells are selected from the group consisting of:
• mammary epithelial cells, mammary myoepithelial cells, and mammary progenitor cells.

A cultured milk product, comprising:

• Beta-casein;
• Alpha-lactalbumin;
• Kappa-casein;
• Alpha-S1-casein;
• Lactoferrin;
• Butrophilin;
• Osteopontin;
• Lactadherin;
• Lysozyme;
• Mucin-4;
• Mucin-1;
• C8:0 (caprylic acid);
• C10:0 (capric acid);
• C12:0 (lauric acid);
• C13:0 (tridecylic acid);
• C14:0 (myristic acid);
• C16:0 (palmitic acid);
• C16:1 (palmitoleic acid);
• C18:2n-6 (linoleic acid, LA);
• C18;3n-3 (alpha-linolenic acid, ALA);
• C20:3n-6 (dihomo-gama-linolenic acid, DGLA);
• C20:4n-6 (arachadonic acid, AA);
• C20:5n-3 (eicosopentanoic acid, EPA);
• C22:6n-3 (docosahexaenoic acid, DHA);
• C22:1n9 (eruic acid);
• C24:1 (nervonic acid);
• Lactose;
• Glucose;
• 3′-SL;
• 6′-SL;
• LNT;
• LNnT;
• 9-hydroxyoctadecadienoic acid (9-HODE);
• 13-hydroxyoctadecadienoic acid (13-HODE);
• 5,15-dihydroxyeicosatetraenoic acid (5,15-DiHETE);
• 17,18-dihydroxyeicosatetraenoic acid (17,18-DiHETE);
• 8,9-Dihydroxyicosatrienoic acid (8,9-DiHETrE);
• 11,12-Dihydroxyicosatrienoic acid (11,12-DiHTETrE);
• 9,10-dihydroxyoctadecenoic acid (9,10-DiHOME);
• 12,13-dihydroxyoctadecenoic acid (12,13-DiHOME);
• 14(15)-epoxyeicosatrienoic acid (14(15)-EpETre);
• 19(20)-epoxydocosapentanoic acid (19(20)-EpDPE);
• 17-hydroxydocosahexaenoic acid (17-HDoHE);
• 5-hydroxyeicosatetraenoic acid (5-HETE);
• 8-hydroxyeicosatetraenoic acid (8-HETE);
• 9-hydroxyeicosatetraenoic acid (9-HETE);
• 11-hydroxyeicosatetraenoic acid (11-HETE);
• 12-hydroxyeicosatetraenoic acid (12-HETE);
• 9-hydroxyoctadecatrienoic acid (9-HOTrE);
• 9-oxo-octadecadienoic acid (9-oxo-ODE);
• or 13-oxo-octadecadienoic acid (13-oxo-ODE);
• 17,18-epoxyeicosatetraenoic acid (17(18)-EpETE;
• 6-Keto-prostaglandin F1alpha (6-keto-PGF1a);
• or 15(S)-Hydroxyeicosatrienoic acid (15(S)-HETrE);
• and slgA;
• wherein the cultured milk product does not comprise or is substantially free of persistent organic pollutants (POPs), heavy metals, prescription drugs, recreational drugs, allergens, cells, hormones, or virus;
• provided that the cultured milk product may comprise human mammary epithelial cells or plasma cells.

A method of producing isolated sIgA from mammary cells, the method comprising:

• a. culturing a cell construct in a bioreactor under conditions which produce a cultured milk product, said cell construct comprising:
• i. a three-dimensional scaffold having an exterior surface, an interior surface defining an interior cavity, and a plurality of pores extending from the interior surface to the exterior surface;
• ii. a matrix material disposed on the exterior surface of the three-dimensional scaffold;
• iii. a culture media disposed within the interior cavity and in fluidic contact with the internal surface;
• iv. a plurality of plasma cells disposed on the matrix material;
• and
• v. a confluent monolayer of polarized mammary cells disposed on the plurality of plasma cells, wherein the mammary cells are selected from the group consisting of:
• mammary epithelial cells, mammary myoepithelial cells, and mammary progenitor cells, wherein the polarized mammary cells comprise an apical surface and a basal surface;
• and
• b. isolating the sIgA from the cultured milk product.